Key facts
- Notable investors include Tech Incubator Program for Startup, IBK Changgong, FuturePlay, Hana Ventures, Devsisters Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for biobricks
- ·The full record, as it builds
Funding rounds
No funding rounds for biobricks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About biobricks
Developer of organ-ink-based tissue and organ manufacturing technology designed for bioprinting and regenerative medicine purposes. The company's decellularized extracellular matrix is used to cultivate various cell lines, including stem cell-derived organoids, enabling clients from the healthcare industry to create an organ-specific microenvironment to promote regenerative capacity
- Sector
- Healthcare
- HQ
- Pohang, South Korea
- Founded
- 2022
- Website
- biobricks.kr/
- Ownership
- Privately Held (backing)
biobricks doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in biobricks shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on biobricks in its N-PORT filings yet. We sweep new filings monthly.